Medicare Ends Special Payment Pathways for New FDA Breakthrough Devices
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
From October 2026, newly designated FDA breakthrough devices will no longer qualify automatically for supplementary inpatient and outpatient Medicare payments. CMS ended pathways that since 2020 had waived requirements to prove substantial clinical improvement or novelty.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu